Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice
Authors:
Open Access
- 17 June 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Targeting cell cycle has become the gold standard for metastatic breast cancer (MBC), being cyclin-dependent kinase inhibitors (CDKIs) cornerstones of its treatment, alongside radiotherapy (RT). To date, no definite evidence regarding safety and efficacy of the combination of CDKIs plus radiotherapy (RT) is currently available. Purpose of this review is to collect data in favor or against the feasibility of the association of CDKIs + RT, describing its potential adverse events. Our review shows how CDKI + RT allows an overall satisfying disease control, proving to be effective and causing a grade of toxicity mainly influenced by the site of irradiation, leaning to favourable outcomes for sites as liver, spine or brain and to poorer outcomes for thoracic lesions or sites close to viscera; controversial evidence is instead for bone treatment. Toxicity also varies from patient to patient. To sum up, our contribution enriches and enlightens a still indefinite field regarding the feasibility of CDKIs + RT, giving cues for innovative clinical management of hormone-responsive MBC.Keywords
This publication has 30 references indexed in Scilit:
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast CancerJournal of Clinical Oncology, 2017
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine TherapyJournal of Clinical Oncology, 2017
- MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast CancerClinical Cancer Research, 2017
- Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 ResultsThe Oncologist, 2017
- A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and LymphomasClinical Cancer Research, 2016
- Palbociclib and Letrozole in Advanced Breast CancerNew England Journal of Medicine, 2016
- Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectivesAnnals of Oncology, 2016
- Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast CancerBreast Care, 2016
- Targeting CDK4/6 in patients with cancerCancer Treatment Reviews, 2016
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker AssessmentClinical Cancer Research, 2015